PT - JOURNAL ARTICLE AU - Douaud, Gwenaëlle AU - Lee, Soojin AU - Alfaro-Almagro, Fidel AU - Arthofer, Christoph AU - Wang, Chaoyue AU - McCarthy, Paul AU - Lange, Frederik AU - Andersson, Jesper L.R. AU - Griffanti, Ludovica AU - Duff, Eugene AU - Jbabdi, Saad AU - Taschler, Bernd AU - Keating, Peter AU - Winkler, Anderson M. AU - Collins, Rory AU - Matthews, Paul M. AU - Allen, Naomi AU - Miller, Karla L. AU - Nichols, Thomas E. AU - Smith, Stephen M. TI - SARS-CoV-2 is associated with changes in brain structure in UK Biobank AID - 10.1101/2021.06.11.21258690 DP - 2022 Jan 01 TA - medRxiv PG - 2021.06.11.21258690 4099 - http://medrxiv.org/content/early/2022/03/02/2021.06.11.21258690.short 4100 - http://medrxiv.org/content/early/2022/03/02/2021.06.11.21258690.full AB - There is strong evidence for brain-related abnormalities in COVID-191–13. It remains unknown however whether the impact of SARS-CoV-2 infection can be detected in milder cases, and whether this can reveal possible mechanisms contributing to brain pathology. Here, we investigated brain changes in 785 UK Biobank participants (aged 51–81) imaged twice, including 401 cases who tested positive for infection with SARS-CoV-2 between their two scans, with 141 days on average separating their diagnosis and second scan, and 384 controls. The availability of pre-infection imaging data reduces the likelihood of pre-existing risk factors being misinterpreted as disease effects. We identified significant longitudinal effects when comparing the two groups, including: (i) greater reduction in grey matter thickness and tissue-contrast in the orbitofrontal cortex and parahippocampal gyrus, (ii) greater changes in markers of tissue damage in regions functionally-connected to the primary olfactory cortex, and (iii) greater reduction in global brain size. The infected participants also showed on average larger cognitive decline between the two timepoints. Importantly, these imaging and cognitive longitudinal effects were still seen after excluding the 15 cases who had been hospitalised. These mainly limbic brain imaging results may be the in vivo hallmarks of a degenerative spread of the disease via olfactory pathways, of neuroinflammatory events, or of the loss of sensory input due to anosmia. Whether this deleterious impact can be partially reversed, or whether these effects will persist in the long term, remains to be investigated with additional follow up.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was primarily supported by a Wellcome Trust Collaborative Award 215573/Z/19/Z. K.L.M. was supported by a Wellcome Trust Senior Research Fellowship 202788/Z/16/Z. The Wellcome Centre for Integrative Neuroimaging (WIN FMRIB) is supported by centre funding from the Wellcome Trust (203139/Z/16/Z). S.L. was supported by the Rina M. Bidin Foundation Fellowship in Research of Brain Treatment and the Pacific Parkinsons Research Institute. P.K. was supported by the UK Research and Innovation (MR/S034978/1). P.M.M. acknowledges generous personal and research support from the Edmond J. Safra Foundation and Lily Safra, an NIHR Senior Investigator Award, the UK Dementia Research Institute and the NIHR Biomedical Research Centre at Imperial College London. This research has been conducted in part using the UK Biobank Resource under Application Number 8107. We are grateful to UK Biobank for making the data available, and to all UK Biobank study participants, who generously donated their time to make this resource possible. We would like to thank Profs. Bruce Fischl and Doug Greve on guidance with the FreeSurfer analyses. Analysis was carried out at the Oxford Biomedical Research Computing (BMRC) facility. BMRC is a joint development between the Wellcome Centre for Human Genetics and the Big Data Institute, supported by Health Data Research UK and the NIHR Oxford Biomedical Research Centre.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Human subjects: UK Biobank has approval from the North West Multi-centre Research Ethics Committee (MREC) to obtain and disseminate data and samples from the participants (http://www.ukbiobank.ac.uk/ethics/), and these ethical regulations cover the work in this study. Written informed consent was obtained from all participants.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData can be accessed through the UK Biobank.